Second Malignancies Following Treatment in non-Hodgkin's Lymphoma

References

• Pedersen-Bjergaard J. Therapy-related acute non-lymphocytic leukemia: Clinical aspects. Med. Oncol. Tumor Pharmacother 1988; 5: 207–209
   PubMedGoogle Scholar
• Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N. Eng. J. Med 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• Lishner M., Prokocimer M., Ron E, et al. Primary malignant neoplasms associated with chronic lymphocytic leukemia. Postgrad. Med. J 1987; 63: 253–256
   PubMed Web of Science ®Google Scholar
• Neglia J. P., Meadows A. T., Robinson C, et al. Second neoplasms after acute lymphoblastic Leukemia in childhood. N. Eng. J. Med 1991; 325: 1330–1336
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Ersboll J., Sorensen H. M., Niles K., Larsen S. O., Philip P. Risk of acute nonlymphocytic Leukemia and preLeukemia in patients treated with cyclo-phosphamide for non-Hodgkin's lymphoma. Ann. Intern. Med 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Greene N. H., Young R. C., Merrill J. M., DeVita V. T. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891–1898
   PubMed Web of Science ®Google Scholar
• Zarrabi M. H. Association of non-Hodgkin's lymphoma and second neoplasms. Sem. Oncol 1990; 7: 340–351
   Google Scholar
• Rosner F. Cancer and secondary leukemia. Bull. Cancer (Paris) 1983; 70: 55–60
   PubMed Web of Science ®Google Scholar
• Zarrabi M. H. Association of non-Hodgkin's lymphoma and second neoplasms. Sem. Oncol 1990; 17: 120–132
   PubMed Web of Science ®Google Scholar
• O'Donnel J. F., Brereton H. D., Greco A. F., Gralnick H. R., Johnson R. F. Acute nonlymphocytic Leukemia and acute myeloproliferative syndrome following radiation for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Clinical studies. Cancer 1979; 44: 1930–1938
   PubMed Web of Science ®Google Scholar
• Gomez G. A., Aggarwal K. K., Han T. L. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic Leukemia in non-Hodgkin's lymphoma. Correlation with intensity of treatment. Cancer 1982; 50: 2285–2288
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Second malignancies associated with chemotherapeutic agents. Sem. Oncol 1982; 9: 131–142
   PubMed Web of Science ®Google Scholar
• Grunwald H., Rosner F. Acute Leukemia and immunosuppresive drug use: A review of patients undergoing immunosuppresive therapy for non-neoplastic diseases. Arch. Intern. Med 1979; 139: 461–466
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P. Therapy related malignancies: A review. Eur. J. Hematol 1989; 42(Suppl 48)39–47
   Google Scholar
• Green M., Harris E., Gersnenson D, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann. Intern. Med 1986; 105: 360–367
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Keating M., Walters R., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Therapy related Leukemia and myelodysplastic syndrome: Clinical, cytogenetic and prognostic features. J. Gin. Oncol 1986; 4: 1748–1757
   Web of Science ®Google Scholar
• Hellrian S., Moloney W. C., Meissner W. A. Paradoxical effect of radiation on tumor incidence in the rat: Implications for radiation therapy. Cancer Res 1982; 42: 433–436
   PubMed Web of Science ®Google Scholar
• Lavey R. S., Eby N. L., Prosnitz L. R. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Kaldor J. M., Day N. E., Clarke A, et al. Leukemia following Hodgkin's disease. N. Eng. J. Med 1990; 332: 7–13
   Web of Science ®Google Scholar
• Lishner M., Slingerland J., Barr J., Panzarella T., Degendorfer P., Sutcliffe S. Second malignant neoplasms in patients with non-Hodgkin's lymphoma. Hematol. Oncol 1991; 9: 169–179
   PubMed Web of Science ®Google Scholar
• Levine E. G., Bloomfield C. D. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Sem. Oncol 1992; 19: 47–84
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Chemotherapy and bone marrow transplantation for myelodysplastic syndrome. Sem. Oncol 1992; 19: 85–94
   PubMed Web of Science ®Google Scholar
• Burin N. J., Casper J. T., Chitamba C, et al. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J. Clin. Oncol 1988; 6: 1851–1855
   PubMed Web of Science ®Google Scholar
• Gajewski J. L., Ho W. G., Feig S A., et al. Bone marrow transplantation using unrelated donors for patients with advanced Leukemia or bone marrow failure. Transplantation 1990; 50: 244–249
   PubMed Web of Science ®Google Scholar
• Konits P. H., Aisner J., Whitacre M., Wiernik P. H. Lung cancer as a complication of prolonged survival in patients with lymphoma. Med. Ped. Oncol 1982; 10: 331–338
   PubMedGoogle Scholar
• Berg J. W. The incidence of multiple primary cancers: I Development of further cancers in patients with lymphomas, leukemias and myeloma. J. Natl. Cancer Inst 1967; 38: 741–752
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Diamond H. D., Jaslowitz B, et al. Lymphosarcoma: A review of 1269 cases. Medicine 1961; 40: 31–84, (Baltimore)
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Ersboll J., Hansen V. L., Sorensen B. L., Christoflersen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N. Eng. J. Med 1988; 318: 1028–1032
   PubMed Web of Science ®Google Scholar
• Travis L. B., Curtis L. E., Boke J. D., Jr., Hankey B. F., Fraumeni J. F., Jr. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67: 2002–2009
   PubMed Web of Science ®Google Scholar
• Golub G. R., Kefemine A. A. Multiple malignancies in lymphoproliferative disorders diagnosed by needle aspiration biopsy of pulmonary lesions. Cancer 1980; 231: 725–729
   Google Scholar
• Aberuathy D., Beltran G., Stuckey W. J. Lung cancer following treatment for lymphoma. Am. J. Med 1986; 8: 215–218
   Web of Science ®Google Scholar
• MacDougall B. K., Weinerman B. H., Kernel S. Second malignancies in non-Hodgkin's lymphoma. Cancer 1981; 48: 1299–1301
   PubMed Web of Science ®Google Scholar
• Mossman K. L. Ionising radiation and cancer. Cancer Invest 1984; 2: 301–310
   PubMed Web of Science ®Google Scholar
• Kohn H. I., Fry R. J. M. Radiation carcinogenesis. N. Eng. J. Med 1984; 310: 504–511
   PubMed Web of Science ®Google Scholar
• Meadows A. T. Risk factors for second malignant neoplasms: report from the Late Effects Study Group. Bull. Cancer 1988; 75: 125–130
   PubMed Web of Science ®Google Scholar
• Travis L. B., Curtis R. E., Boice J D., et al. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma. N. Eng. J. Med 1989; 321: 544–545
   PubMed Web of Science ®Google Scholar
• Brock N., Stekar J., Pohl J., Niemeyer U., Schemer G. Acrolein, the causative factor of urotoxic side-effect of cyclophosphamide, ifosfamide, sufosfamide. Arzneimittelfor-schung 1979; 291: 659–661
   Google Scholar
• Canellos G. P., DeVita V. T., Arsenean J. C., Whang-Peng J., Johnson R. E. Second malignancies complicating Hodgkin's disease in remission. Lancet 1975; 1: 947–949
   PubMed Web of Science ®Google Scholar
• Bookman M. A., Longo D. L., Young R. C. Late complications of curative treatment in Hodgkin's disease. JAMA 1988; 260: 680–683
   PubMed Web of Science ®Google Scholar
• Fisher R. I., DeVita V. T., Bostick F, et al. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann. Intern. Med 1980; 92: 595–599
   PubMed Web of Science ®Google Scholar
• Rowley J., Golomb H., Vardiman J. Nonrandom chromosome abnormalities in acute Leukemia and dysmyelo-poietic syndrome in patients with previously treated malignant disease. Blood 1981; 58: 759–767
   PubMed Web of Science ®Google Scholar
• Fourth international workshop on chromosomes in Leukemia. Secondary neoplasms associated with neoplasia: treated and untreated. Cancer Genet. Cytogenet 1984; 12: 95–104
   PubMedGoogle Scholar
• Le Beau M. M., Epstein M D., et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc. Nat. Acad. Sci. USA 1987; 84: 5913–5917
   PubMed Web of Science ®Google Scholar
• Le Beau M., Albain K., Larson R, et al. Clinical and cytogenetic correlations in 63 patients with therapy related myelodysplastic syndrome and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes 5 and 7. J. Clin. Oncol 1986; 4: 325–345
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J. Therapy-related Leukemia and myelodysplastic syndrome. Sent. Oncol 1987; 14: 435–443
   PubMed Web of Science ®Google Scholar
• Murphree A., Benedict W. Retinoblastoma: Clues to human oncogenesis. Science 1984; 223: 1028–1033
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Janssen T. W. G. Point mutation of the ras protooncogenes and chromosomal aberrations in acute nonlymphocytic Leukemia and preLeukemia related to therapy with alkylating agents. Cancer Res 1988; 48: 1812–1817
   PubMed Web of Science ®Google Scholar
• Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Libshitz H. I., Zornoza J., McCarty J. W. Lung cancer in chronic Leukemia and lymphoma. Radiology 1978; 127: 297–300
   PubMed Web of Science ®Google Scholar
• Kapadia S. B., Krause J. R., Lawrence D. E., Pan S. F., Wald N. Induced acute nonlymphocytic Leukemia following long term chemotherapy. Cancer 1980; 45: 1315–1321
   PubMed Web of Science ®Google Scholar